DISCOUNT-ZERTIFIKAT - MODERNA Share Price

Certificat

DE000KH38WB1

Market Closed - Deutsche Boerse AG 11:05:34 14/06/2024 pm IST
93.21 EUR +0.37% Intraday chart for DISCOUNT-ZERTIFIKAT - MODERNA
Current month+1.67%
1 month+1.82%
Date Price Change
14/24/14 93.21 +0.37%
13/24/13 92.87 +0.97%
12/24/12 91.98 -0.94%
11/24/11 92.85 +0.21%
10/24/10 92.66 +0.46%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 11:05 pm IST

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying MODERNA, INC.
IssuerLogo Issuer Citi Citi
WKN KH38WB
ISINDE000KH38WB1
Date issued 10/03/2023
Cap 100 $
Last trading day 20/06/2024
Maturity 20/06/2024 (4 Days)
Parity 1 : 1
Emission price 78.47
Emission volume N/A
Payment day 26/06/2024
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 0.000000 %
Sideways yield 0.000000 %
Sideways yield pa 0.000000 %
Outperformance point- $
Break even 0.000000 €
Highest since issue 93.49
Lowest since issue 59.56
Distance Cap 40.03 $
Distance Cap %+28.59%
Max. earning-
Max. earning % 0.000000 %

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140 USD
Average target price
145.2 USD
Spread / Average Target
+3.67%
Consensus